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Abstract
In the proteomic mass spectrometry field, peptide and protein identification can be
classified into two categories: database search that relies on existing peptide and protein
databases and de novo sequencing with no prior knowledge. There are many unknown
protein sequences in nature, especially those proteins that play an vital role in drug devel-
opment pipelines, such as monoclonal antibodies and venoms. To sequence these unknown
proteins, de novo sequencing is a necessity.
There have been standard algorithms for de novo sequencing a short peptide from its
tandem mass spectrum (MS/MS). However, the de novo sequencing of a whole protein is
still in its infancy.
The most promising method is to digest the protein into overlapping short peptides with
different enzymes. After each peptide is de novo sequenced with MS/MS, these overlapping
peptides are then assembled together either manually or with a computer algorithm. Such
an automated assembly algorithm becomes the main purpose of this thesis.
Compared to the DNA sequence assembly counterpart, the main challenges are the
high error rates and the short sequence length of each de novo peptide. To meet these
challenges, novel scoring methods and algorithms are proposed and a software program
is developed. The program is tested on a standard data set and demonstrates superior
performance when compared to the state-of-the-art.
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Chapter 1
Introduction
1.1 Motivation
In the computational proteomics field, most studies are focusing on identifying proteins by
digesting sample proteins into peptides with enzymes, generating a tandem mass (MS/MS)
spectrum for each peptide precursor, and then identifying the peptide sequence of each
MS/ MS spectrum with a database search tool. Protein databases are generated from gene
sequences within a given genome. However, due to sequence variation and the existence
of unsequenced genomes, many protein sequences remain unknown. The sequences of
some proteins, which are crucial in many therapeutic drug development pipelines, are
not included in protein databases during the research stage. For example, trastuzumab
(Herceptin) and alemtuzumab (MabCampath), which are monoclonal antibodies, have
been successfully used on patients with breast cancer and graph-versus-host disease [22].
Captopril, a venom-based drug, has been successfully used on patients with cardiovascular
disease[15] [16].
De novo protein sequencing was introduced for sequencing those proteins that are not
included in the databases. Sometimes, even when a protein sequence is known, de novo
protein sequencing can be utilized to discover novel forms of the protein generated from
unexpected mutations, splicing events, and post-translational modifications (PTMs). Over
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20 years ago, Johnson and Biemann sequenced a complete protein from rabbit bone marrow
by manual interpretation of mass spectrometry data [13]. Edman degradation is another
approach for sequencing novel proteins but it has limitations that make it unsuitable for
sequencing proteins if the N-terminal amino acid has been chemically modified or if it is
concealed within the body of the protein.
Fully automated de novo sequencing of unknown proteins is still a challenging problem.
Experimental results are limited by ambiguous de novo interpretations, short peptide length
and incomplete peptide fragmentation.
1.2 Research Objectives
In [3], Bandeira et al. proposed the shotgun protein sequencing (SPS) method, which
obtains high coverage and accuracy. Sometimes, even if the target protein sequence is not
included in the database, its homologous protein sequences are available. Comparative
shotgun protein sequencing (cSPS) combines homologous sequences and SPS to improve
de novo sequence coverage and accuracy [2]. Another method, meta-SPS [10] was proposed
by Guthals et al. by assembling tandem mass (MS/MS) spectra from overlapping peptides.
CHAMPS [17] first uses de novo peptide sequencing to interpret bottom-up MS/MS. Then
the method uses a homologous sequence to align those peptide sequences to find overlap-
ping peptide sequences and their positions relative to the homologous sequence. Finally,
the peptide sequences are assembled to acquire a protein sequence. A de novo protein se-
quencing combining top-down and bottom-up MS was introduced in [16]. In their method,
a top-down tandem mass spectrum is utilized as a scaffold, and bottom-up tandem mass
spectra are aligned to the scaffold to increase sequence coverage.
The methods mentioned above either realize protein sequencing by assembling some
type of mass spectra or use some kind of references to guide the alignment. However, with
the development of mass spectrometry technology, new kinds of spectral data will be intro-
duced. As a result, these mass spectrum based method should be changed accordingly. On
top of that, we can not expect that there is always a homologous sequence in the database.
Reference based methods are still limited when unknown sequences are encountered. Thus,
2
in the new method, we focus on three objectives:
• Implement an automated assembly method to generate long length de novo protein
sequence at high accuracy from mixed protein samples
• Operate directly on de novo peptides rather than mass spectra. By separating the
de novo sequencing process from assembly process, we are no longer troubled by any
upgrades in the mass spectrometry technology. Any improvements in the de novo
sequencing field will be reflected in the results of our method. Besides, compared to
the mass spectrum, the de novo peptide is a less complicated object. It is what the
peptide originally looks like. Thus, compared to the mass spectrum based methods,
de novo peptide based assembly allows the algorithm design effort to be focused on
the result accuracy rather than dealing with the complexities of the spectral data.
• Remove the dependency on any reference protein sequences. By discarding reference
data, like homologous sequence or top-down tandem mass spectra, this method is
very promising in real situations where no related records of the experimental data
can be found in the database.
1.3 Overview of the Thesis
The thesis is structured in the following chapters. In Chapter 2, we briefly review funda-
mentals for MS-based proteomics, such as mass spectrometry technology, database search
approach and de novo sequencing approach. Chapter 3 presents some related works, such
as CHAMPS [17], Meta-SPS[10] and TBNovo[16]. The details of the design of our novel
idea, a de novo peptide based greedy algorithm, are included in Chapter 4. Implementa-
tion and experiments results are also provided in Chapter 4. Conclusions are presented in
Chapter 5.
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Chapter 2
Background
2.1 Fundamentals of mass spectrometry (MS)
Mass spectrometry
Mass spectrometry is an analytical technique that sorts ions based on their mass-to-charge
ratio. It works by ionizing chemical compounds to generate charged molecules and mea-
suring their mass-to-charge ratios. The mass is usually measured in Dalton (Da), which is
1/12 of the mass of a carbon atom, and is approximately the mass of a hydrogen atom. A
mass spectrum is a plot of the ion signal as a function of the mass-to-charge ratio, which is
used for analyzing the elemental composition of a sample or molecule, and for elucidating
the chemical structures of molecules, such as peptides and other chemical compounds.
4
Figure 2.1: The basic components of a mass spectrometer (orbitrap [25])
As shown in Figure 2.1, a mass spectrometer consists of three parts: an ion source,
a mass analyzer and a detector. The ionizer converts molecules or atoms into charged
particles, which are called ions. In mass analyzer, which is the orbitrap in our example,
ions are electrostatically trapped in an orbit around a central, spindle shaped electrode.
The electrode confines the ions so that they both orbit around the central electrode and
oscillate back and forth along the central electrode’s long axis. This oscillation generates an
image current in the detector plates which is recorded by the instrument. The frequencies
of these image currents depend on the mass to charge ratios of the ions. Mass spectra are
obtained by Fourier transformation of the recorded image currents[26].
There are several ionization techniques, depending on the phase (solid, liquid, gas) of the
sample and the efficiency of various ionization mechanisms for the unknown species. Two
techniques often used with liquid and solid biological samples are electrospray ionization
(ESI, invented by John Fenn [5]) and matrix-assisted laser desorption/ionization (MALDI,
developed by M. Karas and F. Hillenkamp [14]). ESI produces ions using an electrospray
in which a high voltage is applied to a liquid to create an aerosol. It is especially useful in
producing ions from macromolecules because it overcomes the propensity of these molecules
5
to fragment when ionized. MALDI is a soft ionization technique used in mass spectrometry,
allowing the analysis of biomolecules and large organic molecules, which tend to be fragile
and fragment when ionized by more conventional ionization methods. Comparing with
ESI, MALDI produces far fewer multiply charged ions.
There are two important parameters of a mass analyzer: mass resolving power, which
is the measure of the ability to distinguish two peaks of slightly different mass-to-charge-
ratio, and mass accuracy, which is the ratio of the m/z measurement error to the true m/z.
It is usually measured in ppm (parts per million, 10−6). Mass analyzers commonly used
in proteomics are: quadrapole, time-of-flight (TOF), ion trap and Fourier transform ion
cyclotron resonance (FT).
The detector records either the charge induced or the current produced when an ion
passes by or hits a surface. In a scanning instrument, the signal produced in the detector
during the course of the scan versus where the instrument is in the scan will produce a
mass spectrum. In orbitraps, the detector consists of a pair of metal surfaces within the
mass analyzer/ion trap region which the ions only pass near as they oscillate. No direct
current is produced, only a weak AC image current is produced in a circuit between the
electrodes, which is then converted to m/z spectrum.[26].
Tandem Mass Spectrometry
Tandem mass spectrometry, also known as MS/MS, involves two steps of mass spectrometry
selection, with some form of fragmentation occurring in between the stages [9]. In a tandem
mass spectrometer, in the first stage of mass spectrometry (MS1), ions are formed in the
ion source and separated by mass-to-charge ratio. Ions from first stage are also called
precursor ions or parent ions. These ions are then separated and detected in a second
stage of mass spectrometry (MS2 or MS/MS), as shown in Figure 2.2. The scan which
measures the peptides entering the spectrometer during a fixed time interval in the first
stage is called survey scan or MS scan. Subsequently, a particular peak in the MS scan
is selected. The instrument will fragment the corresponding ion and measure its product
ions to form an MS/MS scan. Usually, one MS scan is followed by one to four MS/MS
scans, each targeting a different peak in the MS scan.
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Figure 2.2: Schematic of tandem mass spectrometry
Figure 2.3 illustrates the possible fragmentation sites of a peptide. Fragment ions are
labeled consecutively from the N-terminus (amino group) as a, b and c-ions, and also from
the C-terminus (carboxyl group) as x, y, and z-ions. The most common and informative
ions are generated by fragmentation at the amide bond between amino acids, resulting in
b-ions if the charge is retained by the N-terminal part of the peptide and y-ions if the
charge is retained by the C-terminal part.
Figure 2.3: Fragmentation sites of a peptide.
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There are various methods to fragment molecules in MS/MS, including collision in-
duced dissociation (CID), electron transfer dissociation (ETD), higher energy collisional
dissociation (HCD) and others.
CID is currently the most commonly used fragment method, while other methods are
used to enrich certain types of ions. Under CID condition, the peptide/protein precursor
ion undergoes one or more collisions by interactions with neutral gas molecules, contribut-
ing to vibrational energy which will redistribute over the peptide/protein ion. The vibra-
tional energy can result in ion dissociation occurring at amide bonds along the peptide
backbone, generating b- and y-type fragment ions or leading to losses of small neutral
molecules, such as water and/or ammonia or other fragments derived from side chains. In
general, CID is more effective for small, low-charged peptides. [12] [21]
Complementary to CID fragmentation, electrontransfer dissociation (ETD) that trans-
fers electron to a multiply protonated peptide/protein, could lead to the cleavage of the N-C
α backbone bonds and to generate c- and z-type fragment ions [12]. Different ion types can
provide complementary information for the structural characterization of a certain peptide.
Another important feature of ETD fragmentation is that it can identify CID-labile post
translational modifications (PTMs). Ideally, for peptides with PTMs, ETD can provide
both the sequence information and the localization of the modification sites [21].
Another alternative type of fragmentation method is the high-energy collision dissocia-
tion (HCD). The fragmentation pattern of HCD is featured with higher activation energy
and shorter activation time comparing the traditional ion trap CID. HCD also generates
b and y-type fragment ions. While the higher energy for HCD leads to a predominance of
y-ions, b-ions can be further fragmented to a-ions or smaller species [8], [21]. Without the
low mass cut-off restriction and with high mass accuracy MS2 spectra, HCD has been suc-
cessfully applied for de novo peptide sequencing, providing more informative ion series. As
for PTMs studies, certain diagnostic ions specific for HCD could be recognized for PTMs
identification [4].
In this thesis, the fragmentation methods of our data sets is the combination of col-
lision induced dissociation (CID), electron transfer dissociation (ETD) and higher energy
collisional dissociation (HCD), which takes advantage of corroborating b/y/c/z ions in
8
CID/HCD/ETD.
2.2 Interpret MS/MS Data
Identifying peptides from tandem mass spectrometry (MS/MS) data is an important task
in proteomics. Protein identification from peptide hits and other following analysis are
affected by the accuracy and sensitivity of this task directly. Many software tools have
been developed for peptide identification; these tools can be broadly divided into two
categories: de novo sequencing and database search, as shown in Figure 2.4.
Figure 2.4: Possible ways to interpret MS/MS data [19]
2.2.1 Peptide Identification with DB Search
Peptide Identification with DB Search relies on existing protein databases. In this method,
the first step is to digest the protein mixtures into peptides. The resulting peptides are then
separated with liquid chromatography(LC) before the mass spectrometry measurement.
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Both MS and MS/MS spectra are measured in the experiment. Besides the MS/MS data,
a protein sequence database that contains all the target proteins is given. The primary
task is selecting the correct proteins from the database [18].
There are two steps in the selecting task: identifying peptide sequences from the
database using MS/MS spectrum, and identifying proteins from the grouped peptides.
In the first step, the input, which is the acquired experimental MS/MS spectra data, is
compared with theoretical spectra generated by peptides digested from the protein se-
quences that are in the database. A scoring function is then used to evaluate the similarity
between the experimental data and the theoretical data. A good scoring function is im-
portant for the accuracy of peptide identification. Most commonly used scoring functions
compute the theoretical m/z values of the fragment ions of the peptides, and matches the
peaks of the spectrum with the m/z values. Higher scores are assigned to well matched
spectra. Then the highest scoring peptide is reported as the answer.
After all the peptides are identified, protein identification is still a challenging problem
because of several reasons, for example, not all peptides of a protein can be identified
and each identified peptide may be shared by a few proteins in the database. Protein
identification is the most mature application of mass spectrometry in proteomics. However,
the software in use is still not perfect for reasons mentioned above [18].
The database search is generally believed to be a simpler approach because the protein
sequence database provides a limited space for the software to search. Therefore, when
a protein sequence database is available, a database search is the most common method
for peptide identification [29]. There are many software tools using the database search
approach, such as Mascot [1], X!Tandem [27], and PEAKS [29]. Until today, database
search is still the most widely used method for peptide, protein identification.
2.2.2 Peptide De novo sequencing
De novo sequencing is another approach for peptide identification. It is typically performed
without prior knowledge of the amino acid sequence. It is the process of interpreting amino
acids from peptide fragment masses of a protein. A de novo sequencing algorithm takes
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an MS/MS spectrum as input, and outputs a peptide sequence that best matches the
spectrum using a scoring function. De novo sequencing computation does not require a
protein database, and it has proven successful for confirming and expanding upon results
from database searches.
The spectrum graph approach is used in some de novo sequencing softwares, such as
SeqMS[6], Lutefisk[23] [24] and PepNovo[7]. This approach converts a spectrum into a
graph, where each vertex corresponds to a possible ion related to a peak. Each edge
connects two vertices whose corresponding ions have a mass difference approximately equal
to the mass of an amino acid. The sequence that will be sought is an optimal path
connecting the two termini, as shown in Figure 2.5. The path starts at vertices that
correspond to the N and C termini [28].
Figure 2.5: Spectrum graph
Another commonly used de novo software package is PEAKS[20]. It uses an algorithm
that differs from the graph approach. The algorithm works directly on the spectrum by
first computing a y-ion matching score and a b-ion matching score at each mass value
11
according to the peaks around it. A penalty value is assigned if there are no peaks around
a mass value. The algorithm then computes many amino acid sequences that maximize the
total scores at the mass values of b-ions and y-ions efficiently . A more accurate scoring
function is used to further evaluate these candidate sequences. The scoring function also
considers other ion types such as immonium ions and internal-cleavage ions. The problem
of ion absence is addressed because the PEAKS model assigns a score (or penalty) for each
mass value. The software also computes a confidence score for each amino acid in the final
result by examining the consensus of the top-scoring peptides [28].
12
Chapter 3
Related Work
Although full-length de novo sequencing of unknown proteins remains a challenging open
problem, progress in this area has already been made by a number of pioneering works.
We review some of these works in this section.
3.1 CHAMPS
An automated protein (re)sequencing with MS/MS and a homologous database method is
proposed in [17]. The method requires that a homologous sequence of the target protein
should be included in a given protein sequence database. Homologous sequence means
the sequenced genome that belongs to a close relative of the studied species. In their
experiment, the homologous sequence is found using PEAKS software. CHAMPS includes
the steps shown in Figure 3.1.
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Figure 3.1: CHAMPS workflow
In the de novo tag mapping step, de novo tags are mapped to the reference sequence
using SPIDER algorithm[11]. A similar peptide from the reference sequence should be
found for each de novo tag. These similar peptides from the reference sequence are called
the homolog tags. During this mapping process, mismatch errors are considered by assign
different weights to different error types. By using SPIDER algorithm, for each de novo tag
and its corresponding homolog tag found at the reference sequence, a predicted “middle
sequence” is generated, which is called spider tag in their method. Many spider tags
have already been anchored onto the reference sequence in this step. Pairwise sequence
alignment between each spider tag and its corresponding homolog tag is also computed by
SPIDER during the mapping. Then in the spider tag assembly step, a score function is
used when merging these pairwise alignments together to minimize the error.
Depending upon the level of similarity between reference and target, CHAMPS can
correct de novo sequencing errors and anchor sequences to the reference. However, the
limitation of this method is that the mapping and assembling step both rely on the con-
dition that a homologous protein of the target protein is included in a known database,
which can not be guaranteed every time.
3.2 MetaSPS
Protein sequencing by merging triplet CID/HCD/ETD MS/MS spectra from overlapping
peptides is introduced in [10]. The process of this method is shown in Figure 3.2.
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Figure 3.2: MetaSPS workflow
First, Meta-SPS uses PepNovo+ to interpret MS/MS fragmentation patterns and con-
vert MS/MS spectra into PRM (prefix residue mass) spectra rather than processing MS/MS
spectra directly. In the spectra, log-likelihood scores are used to replace peak intensities
and peak masses are replaced by Prefix-Residue Masses (cumulative amino acid masses of
N-term prefixes of the peptide sequence). They trained their scoring models for decon-
voluted high-resolution CID, HCD, and ETD MS/MS spectra using multiple data sets.
After training the score model, they merged the CID, HCD and/ or ETD PRM spectrum
from the same precursor into a single merged PRM spectrum, by extracting corroborating
PRMs and SRMs from CID/ ETD and HCD/ETD pairs from PRM spectra and inserting
the corresponding combined PRMs into the merged spectrum.
To merge CID/ETD or HCD/ETD pairs, they consider all PRM/PRM matches, SRM/
SRM (Suffix- Residue Masses, cumulative amino acid masses of C-terminal suffixes of the
peptide sequence) matches with at least one PRM, PRM/SRM and SRM/PRM pairs and
SRM/SRM matches without PRMs in from PRM spectra.
This method assembled tandem mass (MS/MS) spectra from overlapping peptides by
using multiple enzymatic digests, combining electron-transfer dissociation (ETD) with
collision-induced dissociation (CID) and higher-energy collision-induced dissociation (HCD)
fragmentation methods to boost interpretation of long, highly charged peptides and taking
advantage of corroborating b/y/c/z ions in CID/HCD/ETD without using reference se-
quence. However, the process requires complicated mass spectra preprocess and the results
15
are still not satisfactory.
3.3 TBNovo
Top-down tandem mass spectra cover whole proteins. While, top-down tandem mass spec-
tra, even combined, rarely provide full ion fragmentation coverage of a protein. TBNovo,
which is proposed in [16], combines top-down and bottom-up MS to assemble mass spectra
of overlapping peptides. A top-down tandem mass spectrum is utilized as a scaffold, and
bottom-up tandem mass spectra are aligned to the scaffold to increase sequence coverage.
The process of TBNovo is shown in Figure 3.3
Figure 3.3: TBNovo workflow
The method only kept a top-down MS/MS spectrum if its precursor mass is the same
(within an error tolerance) to the theoretical precursor mass of the protein. Both top-down
and bottom-up PRM spectra are filtered to remove low quality ones in order to provide
accurate information for de novo sequencing. In the merge step, all top-down PRM spectra
have the same (within an error tolerance) precursor mass are merged into one spectrum to
increase protein coverage. If the mass difference between two PRMs in the merged spectrum
is smaller than an error tolerance, the two PRMs are merged into one by removing the
16
lower intensity one. Then bottom-up Spectra is used to increase the number of correct
PRMs and decrease the number of incorrect PRMs in the top-down spectrum and mapped
to top-down spectra. After refining the top-down PRM spectrum, TBNovo find a protein
sequence P with a corresponding PRM spectrum that best explains the top-down PRM
spectrum by using a spectral graph, where each node represents a PRM.
Combining top-down and bottom-up MS/MS spectra can remove the dependency on
the relative positions in the reference sequence reported by some existing approaches using
only bottom-up MS/MS spectra. However, top-down MS/MS spectra data is not easy to
get, because most laboratories use bottom-up methods to acquire MS/MS spectra.
17
Chapter 4
Methodology
4.1 Method
As detailed in Chapter 1, fully automated de novo sequencing of unknown proteins is still
a challenging problem, because experimental results are mainly limited by ambiguous de
novo interpretations, short peptide length and incomplete peptide fragmentation. Existing
methods to solve this problem are mainly mass spectra based. However, compared to the
mass spectrum, the de novo peptide is a much simpler object because we can simply treat
it as a string. As detailed in section 1.2, assembling those de novo peptides directly by
using the overlap information between them rather than merging mass spectra is a better
and more straightforward method.
To validate our idea, we first design an experiment. In this experiment, database
search results and de novo sequencing results for the same protein are obtained by using
PEAKS [20]. Then the peptide from database search was replaced by the de novo peptide
interpreted from the same MS/MS spectrum. We observed that the information of peptide
overlap indeed provides us with some guidance for protein sequencing.
One critical problem we need to solve is how to use this overlap information. One
natural thought is to keep assembling these overlapping peptides until there are no peptides
to support the assembly process, as shown in Figure 4.1. However, simply assembling
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Figure 4.1: Overlap between de novo tags and assembling process
peptides in this way can not solve the following problems :
• The error in de novo peptides may cause the overlapping parts of two proteins are not
exactly equal. When this happens, how to detect the overlaps, and how to determine
the amino acid sequence of the overlapping part after merging the two peptides?
• Two peptides from different parts of the same protein, or even from two proteins may
have significant overlap due to repeats in the protein. This may lead to erroneous
merging.
• A single inaccurate assembly can mess up all downstream assembly process. We
should have a way to avoid the introduction of errors in the early stage of the assem-
bly.
In this section, we propose a fully automated de novo protein sequencing approach
based on a greedy algorithm. In this algorithm, to solve the assembly problems mentioned
above, a score function is designed to evaluate the quality of the overlap between two
overlapped peptide sequences. Then, the algorithm chooses to assemble the sequence with
the highest score and replaces the original peptide sequence with the assembled sequence.
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4.1.1 Method Overview
Our method utilizes a two-pass approach. The first pass is a traditional de novo sequencing
by using PEAKS software for peptide identification with specified PTMs. Inputs of the
first pass are LC-MS/MS, which are from multiple-enzyme digestions of a group of proteins,
with three fragmentation modes, CID, HCD and ETD. Then we filter out those identified
peptides with a low confidence score. We call these peptides de novo peptide tags. The
second pass merges identified peptides in pairs and replaces the original peptide with the
merged consensus peptide, while evaluating the merging quality. We call the peptide
assembled via overlapping peptide tags that represent a consensus region of protein contig.
The second pass consists of three major steps:
• Peptides pairing and merging: In this step, overlapped peptides are paired.
These peptide pairs are merged using mass match method. After merging, we get
peptide merging candidates and we put them in a candidate table.
• Candidate evaluation using score function: All candidates are scored by com-
bining the peptides overlap score and the support score.
– Overlap score: This feature evaluates the candidate based on how similar the
overlapped part between two merged peptides is.
– Support score: This feature evaluates the candidate based on how well the other
peptides support the merge of the two peptides.
• Candidate competing: The candidate with the highest score is chosen. Then we
need to update the candidate table accordingly.
• Contig merging: Final sequences with long sequence length and high accuracy are
merged.
Our method outputs a confidence score for the final sequence and a local confidence
score for each amino acid within it. The confidence score of the candidate is the average
score of every amino acid. The score is obtained from PEAKS software for each de novo
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peptide initially. Then in the merge step, the confidence score for each amino acid in the
candidate is inherited from its parents for the non-overlapping parts, and updated carefully
for the overlapping amino acids.
4.1.2 Peptide de novo sequencing
For each MS/MS spectrum, the de novo peptide sequence is computed using PEAKS 7.0
software. Each spectrum will associated with a few possible sequences computed by the
software. PEAKS makes no distinction between the amino acids L with I, and K with Q.
In our analysis, we only use the de novo sequence which is the highest scoring sequence of
each spectrum. PEAKS software also outputs a local confidence score for each amino acid
in the sequence and the confidence score for the whole sequence. These two scores are also
recorded for the following analysis.
To minimize the influence of de novo sequencing errors, we first choose a confidence
score threshold to filter out some low quality initial tags obtained from PEAKS. The
confidence score reported by PEAKS, which ranges from 0 to 100%, can illustrate the
accuracy of the de novo peptide tag to some extent. Although a lower confidence score
threshold (e.g. 50%) can include more peptide tags, it will also introduce more de novo
sequencing mistakes and reduce the efficiency. Higher confidence score threshold (e.g. >
80%) can guarantee the correctness, but it will lose a lot of information. We weighed the
pros and cons and decided to included de novo peptide tags with the confidence score
higher than 70%.
4.1.3 Peptides pairing and merging
In our method, to make assembly process happen, we first need to find overlapped peptides
and their overlapped region efficiently. We do not want to waste our time on assembling
two unrelated peptides. To limit our search space, only peptides that can be possibly paired
together should be considered. It is very unlikely that two peptides without any matching
amino acids are actually overlapped in the original protein. So we only considered peptide
pairs that have at least n continuously matching amino acids. In our method, we set n
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to 3. In our experiment, we also tried 4-mers and 5-mers matching. However, by using a
larger n-mer, many possible peptide pairs are missed. If we use a smaller n, false-positive
rate would increase, and we need to spend time on evaluating wrong merging choices. By
using 3-mers, we reduce our search space and minimize the loss of information as much as
possible.
Mass match
Then, to find the border of the overlap region, a mass match method is used. The reason
for using mass match method is that peptides are identified from mass spectra and due to
ambiguous de novo interpretations, instead of having the same amino acids sequence, the
overlapped regions of the peptide pair tends to have the same mass distribution. Rather
than extending the overlapping area by comparing the amino acid, we extend the over-
lapping area by comparing the mass of amino acids, as detailed in Algorithm 1 in section
4.1.7.
After determine the overlap region, we can merge these two peptides, as detailed in
section 4.1.7. After merging, we get a new candidate formed by peptide a and b. The
new candidate consists of three parts, left end, consensus part and right end, as shown in
Figure 4.2.
After merging, we get a candidate table.
Consensus part
Errors will accumulate in the assembled sequence if we only consider the information that
comes from one of the overlapped peptide pairs. To guarantee the quality of the assembled
sequence, we calculate the consensus part between two overlapped peptides. Consensus
part is obtained from the overlap part between peptide tag a and tag b. When doing de
novo sequencing, PEAKS assign confidence score to each amino acid. Our method makes
use of this property to choose more confident amino acid between tag a and b to generate
the consensus part. Details about how to generate consensus part and new candidate are
discussed in section 4.1.7.
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Figure 4.2: Consensus part
The following evaluation is performed on those candidates.
4.1.4 Candidate Evaluation Using Score Function
The algorithm uses a score function to evaluate and choose among peptide merging candi-
dates. The scoring function consists of two parts, the overlap score part and the support
score part. Based on our observation, the longer the overlapping part of two peptides is,
the more likely that the two peptides should be assembled together. However, the overlap
score alone is unable to tell whether an overlap is a real or a false-positive match. Because
peptides from different parts of the protein or different proteins may have very similar
and sometimes the same amino acid sequence. The support score is designed to make the
distinction. The peptide tags used to calculate the support score are called support tags.
Let a, b be the de novo tags, and c i be the support de novo tag, shown in Figure 4.3.
We will define the score function as follows.
score(a, b) = scoreoverlap(a, b) +
3∑
i=1
1
i+ 1
scoresupport(a, b|ci) (4.1)
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Figure 4.3: score(a,b) explanation
Overlap score
The first term of the definition scoreoverlap(a, b) is the overlap score between a and b. Mass
replacement errors are common in peptide de novo sequencing because of the noise in
the mass spectrum and PTM. For example, mass(AT) = mass(TA) and mass(RDG) ≈
mass(VTK), as shown in Table 4.1.
Because of the existence of mass gap errors in the de novo peptides, both exact match
and mass gap match are considered. The definition of this alignment score is:
scoreoverlap(a, b) = max

0
(aaMatch+ α ∗massMatch+
r score− γ) ∗ reliability
(4.2)
• aaMatch is the number of exactly matched amino acids between a and b. We prefer
the overlap with more exactly matched amino acids. This is reasonable because
that the overlap between two peptides is generated by different enzyme cleaving the
protein at different sites. Peptides that are from the same segment in the original
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Table 4.1: Mass replacement table.
Mass Sequence
113.0841 I, L
114.0429 N, GG, D
128.0586 Q, AG
160.0307 C(+57), CG
129.0426 E, Q(+0.98)
170.1055 AV, GL
...
protein will share some common segments. Therefore, the more exactly matched
amino acids these two peptides share, the more likely they are from the same segment.
• massMatch is the number of matched mass gap, as shown in Table 4.1 and Figure
4.3. We include matched mass gap because we are assembling de novo sequencing
tags. De novo sequencing sometimes gives only partially correct tags. The most
common error is that a segment of amino acids is replaced by another segment with
approximately the same masses. As a result, two peptides that are from the same
region may only share limited number of exactly matched amino acids. We will
miss many potential peptide merging candidates if we consider the exact amino acids
match only in this case. We do not count the mass gap that expands more than three
amino acids, because the longer the mass match region is, the more unreliable it is.
According to our observation, matching mass gap that expands more than ten amino
acids can occur between two unrelated sequences, which is obviously not reliable. We
value exact amino acid match more since it is more accurate. We assign a weight α
to massMatch, which is 0.9 in our method.
• r score is served as a reward for the overlap score. Peptide pairs with unmatched
tails or heads are not very reliable. Since de novo sequencing sometimes gives only
partially correct tags and sequencing errors tend to distribute towards to both ends
of the sequence, we cannot determine whether the reason for unmatched left ends
or right ends is the bad pairing choice or the sequencing error. We prefer peptide
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pairs with matched heads or tails and we will give rewards to the peptide merging
candidates that satisfy the following conditions:
– Overlap parts that ends at the end of tag a
– Overlap starts from the beginning of tag b, meanwhile, the amino acid at the
beginning of tag b and the amino acid before the overlap beginning position of
tag a form a cleavage site
• γ is the threshold that can filter some poor-quality assembling. We prefer peptide
pairs with better matching, which means more exactly matched amino acids and high
quality mass gaps. By tuning γ, we can control the merging quality.
• reliability equals to the minimum value between conf b and conf a, which are the
confidence score of tag a and b respectively. In PEAKS[29] software, the confidence
score reflects the accuracy for each de novo tag to a certain extent. In our method, we
hope to obtain assembled sequence with high accuracy, so we tend to choose peptide
pairs having high confidence score as its parents.
Support score
When the overlap information is strong enough, we can get a very promising result. How-
ever, in a real situation, similar and sometimes the same amino acid sequences can appear
at the different segments within the same protein. Besides, de novo sequencing errors are
quite common. We may merge the tag which is in the N-terminal part of the original
protein with the tag that belongs to the C-terminal part of the original protein by mistake
if considering the overlap information only. This problem can be more challenging when
dealing with several proteins at the same time.
However, based on our observation, similar or the same amino acid sequences of two
unrelated peptide tags are unlikely to be very long, and it is very unlikely to find the third
sequence that cover both the matching area and the neighbourhood of the matching area.
On the contrary, if the two peptide tags can form a true merging pairs, either the overlap
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between them can become quite long or there are several tags covering both the overlap
area and the neighbourhood of the overlap area.
Based on the observation, we introduced the support score, scoresupport(a, b|ci) in for-
mula 4.1. Peptide merging candidates are chosen depending on both the overlap score and
the support from other peptide tags that cover both the overlap region and the neigh-
bourhood of the overlap area. Support score is served as a complement score when it is
not enough to distinguish the real match from the false-positive match by overlap score.
Peptide tags used to calculate support scores are called support tags. The support score
is defined as follows:
Assuming the overlap part between a and b is ab overlap, scoreoverlap(ci, aboverlap)
is the overlap score between support tag c i and the ab overlap using the formula 4.3.
score(ci, ableft) and score(ci, abright) are illustrated in Figure 4.4
scoreoverlap(ci, aboverlap) = max
{
0
(aaMatch+ α ∗massMatch− γ) ∗ reliability (4.3)
Figure 4.4: support score
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scoreSupport = min(scoreoverlap(ci, aboverlap), score(ci, ableft), score(ci, abright)) (4.4)
The first method we used to calculate the support score is different than the final
version, which is illustrated as follows. Assuming there is peptide tag c that overlap with
both peptide a and peptide b, we calculate the overlap score between a and c excluding
the overlapping part between a and b using the formula 4.3. We use the same method to
calculate the score between b and c. Then we choose the smaller one from score ac and
score bc as the support score contributed by tag c.
Figure 4.5: support score using first method
However, from our experiments, we found out that the first method we used here cannot
deal with the situation shown in Figure 4.5, peptide a and peptide b have almost the same
amino acid sequences except for the ending part.
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In this case, although the matching score between a,b is low, the support score for ab2
is high. Therefore, using the formula 4.4 to evaluate the support from c to ab2 is more
appropriate. For all the support tags to a candidate, we use formula 4.4 to calculate the
support contributed by one tag and then sort these support tags based on the support
they give. Then we only consider the support from the first three support tags, because
we do not want to give those candidates that have poor overlap quality but are supported
by many support tags priority, like the situation in Figure 4.6. Candidate ab2 is more
reliable than candidate ab1, however, support tags give more support to candidate ab1.
By limiting the number of support tags to 3, we minimize this side effect by introducing
support tags.
Figure 4.6: A candidate with poorer overlap quality but higher support score
4.1.5 Candidate competing
Guaranteeing the correctness of each step is quite important. If we merge a false-positive
match first, we will end up with a mess. As we mentioned in previous section, our score
function can distinguish the real match from a false-positive match by assigning a higher
support score when overlap scores are very close. Thus, by choosing candidate with higher
score first, we exclude the false-positive match. Meanwhile, we prefer the candidate with
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higher quality. According to our score function, candidates generated from merging peptide
pairs that share longer and more reliable overlap regions and those that are supported by
support de novo tags will get higher scores. Thus, choosing candidates with higher scores
first, we give high quality matches priority.
In our method, candidates with different scores compete with each other and we choose
the assembled sequence candidate with the highest score first. After choosing the candidate
with the highest score, we do not consider those candidates involving either one of the
peptide tags which the chosen candidate is generated from anymore.
4.1.6 Contig merging
De novo sequencing software may generate some low quality de novo peptide sequences
and sequencing errors occurred in the initial peptide tags will lead to the inaccuracy in our
final contigs. This kind of inaccuracy tends to appear at the begin and the end part of the
final contigs. And because of this kind of inaccuracy, contigs with long overlap region may
not be merged because of the long non-overlapping head or long non-overlapping tail. To
increase the length our final contigs, we merge more reliable contigs by relaxing merging
conditions.
4.1.7 Algorithms
The overall workflow of our algorithm is shown in Figure 4.7:
• Step 1: Filter out the low quality de novo tags using a chosen threshold. Build a
hash table with remaining peptides to find peptide merging pairs.
• Step 2: Merge peptide pairs and evaluate each resulting candidate.
• Step 3: Choose candidate with highest score and update the contig table and the
candidate table
• Step 4: Repeat step 2 and 3 until the highest score of the candidate is smaller than
a preset threshold
30
• Step 5: Merge final contigs by relaxing the merging condition
We will next cover the various parts of the algorithm details that are necessary to implement
the theory introduced in section 4.1.
Figure 4.7: workflow
How to find peptide pairs
We first filter those initial peptides obtained from PEAKS software. We then build a contig
hash table and a support peptide hash table using 3-mer. The contig table is used to store
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the chosen candidates and it is initialized with those initial peptides. The support peptide
table stores these initial de novo peptide tags for calculating the support score for each
candidate.
Then for a peptide tag a in the contig table, by searching the contig table using each
3-mers in tag a, we can find the possible pairing peptide tag b efficiently. After merging
paired peptides a,b, we can use the support peptide table to find support peptides for
candidate. The process is illustrated in Figure 4.8.
Figure 4.8: Find paired peptides and support peptides
How to merge peptide pairs and calculate the score for each candidate
For peptide tag a, after finding paired peptide tag b, we use the 3-mer as seed, extending
to both sides of a and b by comparing the mass of a to the mass of b until we reach the end
or the mass difference exceeds the threshold (e.g. 1 Dalton in our algorithm). We record
the match begin position and the end position for both a and b, as shown in Algorithm 1.
This mass match algorithm is required in almost every steps in our method.
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Algorithm 1 MassMatch
1: procedure MassMatch
2: pos← positions of seed in tag b
3: for each position p ∈ pos do
4: mass a← mass of seed
5: mass b← mass of seed
6: pos a left← beginning position of seed in tag a
7: pos a right← end position of seed in tag a
8: pos b left← p beginning
9: pos b right← p end
10: i l← pos a left
11: i r ← pos a right
12: j l← pos b left
13: j r ← pos b right
14: while j l ≥ 0 and i l ≥ 0 do . Left side
15: if abs(mass a−mass b) < threshold then
16: pos a left← i l
17: pos b left← j l
18: i l← i l - 1
19: j l← j l - 1
20: mass a = mass b
21: if j l ≥ 0 and i l ≥ 0 then
22: mass a← mass a + mass of a[i l]
23: mass b← mass b + mass of b[j l]
24: else if mass a > mass b then
25: j l← j l - 1
26: if j l ≥ 0 then
27: mass b← mass b + mass of b[j l]
28: else if mass a < mass b then
29: i l← i l - 1
30: if i l ≥ 0 then
31: mass a← mass a + mass of a[i l]
32: mass a← mass of seed mass b← mass of seed
33: while j r ≤ a length and i r ≤ b length do . Expand to right side
34: ... 33
Once we get the overlap region, we can calculate the overlap score between a and b
according to formula 4.2. There are different cases when we merge peptide tag a and tag
b:
Figure 4.9: Overlap cases
Case 1: Tag a contains tag b
Case 2: The right end of tag a overlaps with the left end of tag b
Case 3: The internal tag a overlaps with the internal tag b
For Case 1, we just replaced the overlap part in tag a with the consensus part between
tag a and tag b. Consensus part between a and b is generated as follows:
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Algorithm 2: Calculate consensus sequence
Input: overlap part from tag a: overlap a, overlap part from tag b: overlap b.
Output: Consensus sequence between tag a and b
consensus seq ← “ ”
aa stands for amino acid and mm stands for mass match part
aa a stands for amino acid from tag a and aa b stands for amino acid from tag b
mm a stands for mass match part from tag a and mm b stands for mass match
part from tag b
a conf stands for confidence score of tag a, b conf stands for confidence score
of tag b, mm conf stands for confidence score of mass match part and aa conf
stands for confidence score of amino acid
Loop through the overlap part between tag a and tag b, still using the mass match
method
• for exact matching aa:
consensus seq ← consensus seq + aa
aa score ← max(aa a conf, aa b conf)
• for mass match part between a and b:
mm ← a conf > b conf ? mm a : mm b
consensus seq ← consensus seq + mm
mm conf ← a conf > b conf ? mm a conf : mm b conf
In this way, we get the consensus sequence as well as the confidence score of each amino
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acid in it. In the actual method, we combine this step with overlap score calculation, that
is after calculating overlap score between tag a and tag b, we get the consensus sequence
with confidence score as well.
Case 2 is separated into two parts. The consensus sequence calculation step follows the
same steps above. Then we need to connect the head of tag a and the tail of tag b with
this consensus sequence. Head and tail depend on the longer peptide tag. If tag a has a
longer head, then the head of the candidate comes from tag a. Otherwise, the head of the
candidate comes from tag b. If the heads of the two tags have the same length, then we
choose the head from the more confident tag. Same for the tail.
Case 3 is similar to Case 2, however since de novo sequencing error distributes towards
to both end of the sequence, peptide pairs with unmatched head or tail are not reliable.
We filtered out the merging candidate if the end position of overlap region is too far away
from the end of tag a or the begin position of overlap region is too far away from the
start of tag b. To distinguish between Case 2 and Case 3, we give some rewards to merge
scenarios in Case 2, as mentioned in section 4.1.4.
For each candidate, we use support peptides table to find possible support peptides
and then calculate the support score for each support peptide tag using the mass match
algorithm and formula 4.4.
How to update contig and candidate table
By using formula 4.1, each candidate is associated with a score. We then greedily choose
the candidate with highest score and update our contig table and candidate table until the
highest score is below our threshold. Assuming that the candidate is merged from peptide
tag a and peptide tag b, then we remove tag a and tag b from the contig table, and add
the new candidate into the contig table. Accordingly, we remove all the candidates that
merged from either tag a or tag b from candidate table. We update the candidate table
by using the new candidate as peptide tag, merging it with its paired peptides and adding
the new results into the candidate table. In this way, we can make sure that peptides that
should be merged together with high possibility are chosen first.
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How to merge contigs
In our method, we evaluated final sequences by multiplying their length and confidence
score, because we expect longer sequence with higher accuracy. Then we choose those
sequences with this attribute ranked within top 30 and with confidence score higher than
70. Then we run contig merging on them. The contig merging process is similar to the
peptide pairing and merging. The difference is we relax the merge condition in case3 in
4.9. Because the de novo sequencing errors tend to appear at the head and tail part of the
contigs, instead of filtering the merging candidate, we consider paired contigs if the match
score between them is higher than 10.
Summary
By using the overlap information among de novo peptide tags to merge those pairwise pep-
tides and choose the most promising one to update our dataset, we designed an automated
protein sequencing approach. Experimental results are reported in the next section.
4.2 Experiments and Results
4.2.1 Experiment Overview
In this section, we present experiments on a protein dataset. The dataset includes six target
proteins. Proteins were digested using several enzymes including Arg-C, Asp-N, CNBr,
Glu-C, Lys-C, trypsin and chymotrypsin. Each digest is measured with LC-MS/MS, with
three fragmentation modes, CID, HCD and ETD, respectively. Because different enzyme
cleave the protein at different sites, the peptides generated from a enzyme may overlap with
those from another enzyme. Multiple fragmentation are utilized to produce three MS/MS
spectra for each peptide. This helps increase the de novo sequencing accuracy of each
peptide. The same dataset has been previously used for developing and demonstrating the
performance of the Meta-SPS tool by Guthals et al.
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The performance of our method is assessed in terms of de novo sequencing length,
coverage, and accuracy. Coverage, length and accuracy are determined by comparing the
algorithms’s results with the original proteins. Coverage is calculated by counting the
percentage of amino acids covered in the reference sequence by de novo sequence contig
via error-tolerant alignment. Error-tolerant here means the acceptable mass replacement
mentioned in section 4.1.4.
4.2.2 Results on six target proteins
Overview of sequencing coverage of target proteins
The longest de novo sequencing result, average sequence length and de novo coverage are
reported in the Table 4.2. The longest de novo sequence is the maximum number of amino
acids covered by a single de novo contig. Average sequence length is the average number
of amino acids covered by each aligned de novo contig and contig coverage is the percent
of amino acids in the protein covered by at least one aligned de novo contig.
Table 4.2: De novo sequencing length and coverage
Protein leptin kallikrein groEL myoglobin aprotinin peroxidase
Protein Length(AA) 167 261 548 154 100 353
Longest de novo Sequence(AA) 97 136 170 96 52 65
DB Search Coverage(%) 87.4 89.7 99.8 99.3 67 64
Contig Coverage(%) 87.4 83.5 94.2 99.3 67 56.9
Average Seq. Length(AA)(%) 74.5 82.3 72.4 52.7 31.5 25
In our evaluation, we pay attention to two aspects:
• Single contig length and accuracy. Here we considered the the longest de novo se-
quence and its accuracy for each protein.
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• Protein coverage and accuracy. For protein coverage and accuracy, we considered all
de novo contigs that belong to that protein.
Sequencing coverage comparison
Here we compare our results with Meta-SPS[10], since we are using the data from this
paper. Table 4.3 compares our results with theirs in terms of protein coverage. Our
method results in better sequence coverage for each of the six proteins. Table 4.4 compares
our longest contig length with their longest contig length.
Table 4.3: Multiple de novo contigs coverage comparison
Protein leptin kallikrein groEL myoglobin aprotinin peroxidase
our method(%) 87.4 83.5 94.2 99.3 67 56.9
Meta-SPS (%) 86.2 79.3 80.5 84.4 59 39.9
Table 4.4: Longest de novo contig coverage comparison
Protein leptin kallikrein groEL myoglobin aprotinin peroxidase
our method(AA) 97 136 170 96 52 65
Meta-SPS (AA) 93 134 194 80 59 58
Sequencing accuracy comparison
In de novo peptide sequencing, single amino acid mass replacements are likely to happen,
so we label the exact matched amino acids and single amino acid mass replacements in
our final de novo sequences as correct. Sequencing accuracy is the percentage of all amino
acids that were labeled correct. Meta-SPS[10] only provided their longest de novo sequence,
so we are unable to compare our results with theirs in terms of multiple de novo contig
accuracy. Here, we report the sequence accuracy of our method for each of the six proteins
in table 4.5.
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Table 4.5: De novo sequencing accuracy
Protein leptin kallikrein groEL myoglobin aprotinin peroxidase
Sequencing Accuracy(%) 97.2 87.5 89.4 98.5 97.3 80.1
Table 4.6 compares our longest de novo contig accuracy with the longest sequence
accuracy from Meta-SPS[10]. In Meta-SPS[10], the reversed amino acids were labeled
correct. However, in our calculation, we did not count the reversed amino acids. The
reversed amino acids were shown in Figure 4.10.
Figure 4.10: Reversed amino acids
Table 4.6: Longest de novo contig accuracy
Protein leptin kallikrein groEL myoglobin aprotinin peroxidase
Longest contig accuracy(%) 100 82.7 95.7 100 96.1 61.5
Meta-SPS (%) 82.1 82.2 93.9 100 75.8 90
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Confidence score
As mentioned in the previous section, our method outputs a confidence score for the final
sequence and a local confidence score for each amino acid within it. The confidence score
of the sequence is the average score of every amino acid. From our observation, de novo
sequence with higher confidence score tends to be more accurate. In our results, we set
sequence confidence score as x-axis and sequence accuracy as y-axis, as shown in Figure
4.11. Generally, the sequence accuracy becomes higher as the sequence confidence score
becomes higher.
Figure 4.11: Relationship between de novo sequence confidence and de novo sequence
accuracy
Final de novo sequencing results of six target proteins
In the following, we present the experimental results. Each colored row corresponds to
a de novo sequence, mapped and aligned with the reference protein sequence (without
colored background). In the reference sequences, regions covered with dotted lines indicate
the lack of coverage by database search. Mass gaps are indicated by dashes in sequences.
Missmatches or mass gaps of de novo sequences that expand more than one amino acid
are indicated by red underlines. Below each protein map is the longest de novo sequence
covering that protein from our results and the results from Meta-SPS[10]. Amino acids
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within the brackets correspond to reversed animo acids or incorrect mass interpretation.
Figure 4.12: Sequence coverage of leptin
As shown in Figure 4.12, compared with Meta-SPS, we achieve better sequence coverage
and accuracy. The longest sequence generated for leptin is 97 AA at nearly 100% accuracy.
Errors in the sequence are mainly caused by the mass replacements happened in the de
novo peptide sequencing process.
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Figure 4.13: Sequence coverage of kallikrein related peptidase
As shown in Figure 4.13, the longest sequence generated for kallikrein is 136 AA at
82.7% accuracy. Errors in the sequence are mainly caused by the mass replacement hap-
pened in the de novo peptide sequencing process.
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Figure 4.14: Sequence coverage of groEL
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As shown in Figure 4.14, the longest sequence generated for groEL is 170 AA at 95.7%
accuracy. Our method generated three long-length sequences for groEL. Errors in the
middle part of the sequence are introduced by merging contigs with unmatched heads or
tails.
Figure 4.15: Sequence coverage of myoglobin
As shown in Figure 4.15, compared with Meta-SPS, we achieve better sequence coverage
and accuracy. The longest sequence generated for myoglobin is 96 AA at nearly 100%
accuracy. Errors in the sequence are mainly caused by the amino acid reversals.
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Figure 4.16: Sequence coverage of aprotinin
As shown in Figure 4.16, compared with Meta-SPS, we achieve better sequence coverage
and accuracy. The longest sequence generated for aprotinin is 52 AA at 96.1% accuracy.
The sequence generated by Meta-SPS contains many mass gaps.
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Figure 4.17: Sequence coverage of peroxidase
As shown in Figure 4.17, the longest sequence generated for peroxidase is 65 AA at only
61.5% accuracy. The reason is that, in de novo sequencing, the whole sequence reversal
sometimes happens. The two halves of the peptide are reversed. Our method is not perfect
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for this situation.
4.3 Discussion
Overlap information from PEAKS de novo peptides enable long-length automated de novo
sequencing of protein mixtures at high accuracy without reference. Minor contaminants
would not heavily affect our results. In the experiment, the six target proteins are actually
mixed together, along with some common contaminants in the laboratory environment,
such as human keratin, Lys-C, trypsin precursor and so on. When it comes to a large
dataset, to achieve a better result, we could filter some contaminants by using a contam-
inant library. Although this approach is still unable to reconstruct a complete protein,
the sequence length approached 170 AA at the maximum. While related methods for
de novo protein sequencing are either reference-based or spectrum-based, our method ex-
plores a new research direction in the de novo protein sequencing field by assembling de
novo peptide tags. Free from being troubled by frequent upgrades in the mass spectrom-
etry technology, our methods are able to generate results comparable to the results from
spectrum-based method, such as Meta-SPS. For reference-based method, generally speak-
ing, they can achieve better accuracy, since they have the reference sequence to guide the
whole process. However, reference-based is still limited when we meet a real unknown
sequence. For our method, results could be possibly improved from the following aspects:
• High quality input
The majority of experimental mass spectra are of poor quality. They are not good
enough to be interpreted by de novo methods. For de novo peptide sequencing,
only around 50% of the input mass spectra can be identified. Even for the most
advanced de novo sequencing software, the error rate is around 40% to 50%. Multi
spectrum acquisition of high resolution CID, HCD, and ETD gives us a relatively
better data quality and PEAKS 7.0 software provides us with de novo peptide tags
with relatively higher quality. On top of that, we have tried very hard to avoid
error accumulation in our method by considering the confidence score, constructing
the consensus part and evaluating the merging candidate. We believe that with the
48
development of mass spectrometry and de novo sequencing technologies, the quality
of mass spectra and the accuracy of de novo peptide sequencing will be improved.
With these improvements, our method can achieve better assembly results.
• Peptide fragmentation solutions
Our method is based on the overlap between de novo peptides. A good sample diges-
tion that create more peptide overlaps is crucial to our method. With more overlap
information, our method can obtain much longer and more accurate sequences. To
increase the overlap information, the experimental data is digested using several
enzymes including Arg-C, Asp-N, CNBr, Glu-C, Lys-C, trypsin and chymotrypsin.
Still, increasing the overlap information by trying different enzyme combinations is
a worthy problem to be explored.
• Post-translational modifications
The way we deal with post-translational modifications (PTM) is simple. After the
de novo sequencing step, we just keep the plain amino acid sequence for analysis.
However, if the PTM can be correctly identified by the de novo sequencing step, we
can use the de novo tag directly and assemble them more accurately.
• Advanced score function
The experimental dataset is not easy to get and the lack of large dataset for training
limited the use of an advanced scoring function. We have tried very best to avoid
overfitting by putting robustness as a main consideration in developing the scoring
function. For example, in our experiment, we observed that the signal of most low
accuracy de novo peptide tags, which is because of ambiguous interpretations of
MS/MS fragmentation, tends to be low in the LC-MS (Liquid chromatography-mass
spectra). However, in de novo peptide sequencing, the low accuracy de novo peptide
tags may still have high confidence score. We tried to simply include the intensity
feature in our score function, however, We did not observe significant improvement
in our results. We tried to tune the coefficient of this feature slightly, but the gain is
marginal. To avoid overfitting, we just discarded this feature.
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Chapter 5
Conclusion
5.1 Conclusion
Knowing the sequence of proteins is of great importance because of the many important
functions that proteins may have. The specific contributions and conclusions of this study
can be summarized as follows:
We propose a novel protein de novo sequencing approach to generate de novo sequences.
The input of our method is the mixed protein samples. The key idea is to use the overlap
information among de novo peptide tags to merge those pairwise peptides and choose the
most promising one to update our dataset. We designed an effective score function to
evaluate different merging scheme. Experimental results show that our approach can yield
de novo sequences up to 170 AA at around 96% sequencing accuracy.
5.2 Future work
The objective of this thesis is to design a protein de novo sequencing method to realize de
novo sequencing of unknown proteins without the support from reference sequences. There
remain some problems in our research:
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In our work, we design a score function to evaluate the candidates, which considers the
overlap information, support information, confidence scores and cleavage sites. However,
due to the lack of large data set for training, we only included the limited features to avoid
overfitting. The score function can be further improved once we have enough training data.
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APPENDICES
Appendix A
List of Software and Hardware Used
This section lists the software programs and hardware used. Software List
• PEAKS Studio 7.0
– de novo sequencing and database search
• C++
Hardware List
• Personal Computer: OS X Yosemite Intel(R) Core(TM) i5 CPU @ 2.60 GHz
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